Physician profile
Vivek Agarwal
NPI 1982918199
$4,439.35
in general payments reported to CMS, 2019-2025
32 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $574 · 2021: $136 · 2022: $1,089 · 2023: $980 · 2024: $170 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.16 |
| Education | $186.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $460.80 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $456.46 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $424.05 | 2019-2025 | Tavneos, Parsabiv, Uplizna |
| Astrazeneca Pharmaceuticals LP | $403.13 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $372.57 | 2020-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $293.19 | 2022-2025 | |
| Vifor Pharma, INC. | $255.20 | 2019-2023 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $188.11 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $171.66 | 2019-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $168.18 | 2019 | |
| Calliditas Therapeutics US INC. | $160.32 | 2023-2024 | Tarpeyo |
| Akebia Therapeutics INC | $119.24 | 2019-2023 | Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $116.67 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.01 | 2022-2023 | Gattex |
| Daiichi Sankyo INC. | $95.50 | 2019-2023 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $64.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $58.39 | 2019-2022 | |
| Medtronic, INC. | $50.38 | 2024 | Symplicity G3 |
| Ani Pharmaceuticals, INC. | $50.13 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $46.08 | 2025 | Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $38.97 | 2023 | Benlysta |
| Boston Scientific Corporation | $38.51 | 2021 | |
| Travere Therapeutics, INC. | $38.51 | 2023-2025 | Filspari |
| Bard Peripheral Vascular, INC. | $33.08 | 2021-2023 | Wavelinq |
| Ultragenyx Pharmaceutical INC. | $30.47 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.05 | 2022 | |
| Esperion Therapeutics, INC. | $20.32 | 2020 | |
| Renalytix Ai, INC. | $18.40 | 2022 | |
| Baxter Healthcare | $17.32 | 2019 | |
| Genentech USA, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.